Department of Medicine

Hematology and Oncology Basic Science Research Faculty

Master
Content

The following is a list of basic science research by investigator within the Section of Hematology and Oncology.

Malcolm K. Brenner, M.D., Ph.D.

  • Gene transfer to augment the immune response to human tumors
  • Effects of CD45 monoclonal antibodies on normal and malignant hemopoiesis
     

Akiva Diamond

  • Hodgkin and non-Hodgkin lymphoma, CLL
     

Matthew Ellis

  • Breast cancer oncology
  • Breast cancer genomics
  • Metastatic breast cancer
  • Clinical trials
     

Suzanne A.W. Fuqua, Ph.D.

  • Hypersensitive estrogen receptor in premalignant breast
     

Helen E. Heslop, M.D., M.B.,Ch.B.

  • Translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy
     

Michael T. Lewis, Ph.D.

  • Developmental biology of the mammary gland as it relates to both normal breast function and breast cancer progression
  • Role of hedgehog signal transduction in mammary gland development and breast cancer using the mouse as a model organism
     

Ang Li, M.D.

  • Epidemiological research to prevent and treat cancer-associated thrombosis and thrombotic microangiopathy
  • Clinical trials
     

Fang-Tsyr Lin, M.D., Ph.D.

  • Define the multiple mechanisms by which the EDG family LPA receptors promote cancer invasion, metastasis, and inflammatory responses through G protein-independent signaling, and to verify these effects in vivo
     

Weei-Chin Lin, M.D., Ph.D.

  • Cancer cell cycle
  • Gene expression and regulation
  • DNA damage response
     

Nicholas Mitsiades, M.D., Ph.D.

  • Exploring and targeting the mechanisms involved in hormonal regulation of cancer (in particular of prostate cancer by androgen, and of breast cancer by estrogen)
  • Identifying clinically applicable inhibitors of the expression and/or function of steroid receptor coactivators
  • Investigating the mechanisms involved in the anticancer activity of the diabetes drug metformin and the lipid-lowering drugs HMG-CoA reductase inhibitors (statins)
  • Targeting the signaling pathways triggered by somatic mutations in the G protein α subunits Gαq and Gα11 (encoded by the genes GNAQ and GNA11, respectively) in uveal melanomas
  • Exploring novel therapies for thyroid cancer
     

C. Kent Osborne, M.D.

  • Molecular mechanisms for hormonal resistance in breast cancer: growth factor signaling pathways, phosphorylation of estrogen receptor, and interaction with receptor coregulators
  • Molecular profiling of breast cancers for the identification of prognostic markers to individualize treatment and for the identification of new molecular targets for prevention and treatment
  • Mechanisms of endocrine resistance in breast cancer
  • Gene therapy for the prevention and treatment of breast cancer
     

Carlos Almeida Ramos, M.D.

  • The study of cancer progenitor cells
  • The properties of mesenchymal stromal cells, a population of non-hematopoietic, fibroblast-like cells that have been isolated from bone marrow
     

Mothaffar Fahed Rimawi

  • Management of breast cancer
  • Clinical Trials in breast cancer
  • Neoadjuvant therapy
  • Targeted therapy and biomarkers in breast cancer.
  • HER2-positive breast cancer
     

Aihua Edward Yen

  • Prostate cancer
  • Genitourinary cancers